The intervention group will receive oral hydroxychloroquine. In the first day 400 mg twice daily, followed by 200mg twice daily on days 2-10 (continued after discharge if discharged before day 10).

The control group will not receive hydroxychloroquine.

COVID-19

Hydroxychloroquine

The control group will not receive hydroxychloroquine

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

Number patients developing severe infection or death

Rambam Health Care Campus

Rabin Medical Center

Pediatric Dilated Cardiomyopathy

treatment of anemia.

A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy

Through clinical manifestations of heart of heart failure and echocardiographic assesment of ventricular function

To measure health related quality of life, to monitor the health of populations over time, or to evaluate the efficacy and effectiveness of clinical therapies of practices using a preference weighted self administered measure.

Mohamed Ahmed Amar

principal investigator

Assiut University

Study group 1 CLP with ostectomy Arnica 200 drug 3 pills,3 times daily for 3 days

Study group 2 CLP with ostectomy Diclofenac Sodium 50mg twice daily after meals with plain water

Study group 3 CLP with ostectomy Placebo pills and distilled water 3 pills,3 times daily

Crown Lengthening Procedure With Ostectomy

CLP with ostectomy done in patients whose biologic width and crown height is insufficient

Arnica 200 drug 3 pills,3 times daily for 3 days

Diclofenac Sodium 50mg twice daily

Placebo pills and distilled water 3 pills,3 times daily

Dental

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure: A Placebo Control Trial

Pain Assessment is done by visual analog scale which consists of 10 centimeter line. anchored by two extremes starting from 1 ending to 10, of which 1 being the lowest and 10 being highest score.

Dr.Nibha Suneel Kulkarni

Principal Investigator

Tatyasaheb Kore Dental College

Patients are divided in 6 groups of 3 patients to receive the following intervention: 0 gram (g), 2.5 g, 5 g, 10 g, 12.5 g and 15 g of sodium thiosulfate pentahydrate (STS) intravenous. The first dose is given in 15 min immediately after inclusion at the cath-lab. In the absence of dose-limiting toxicity (DLT), a second gift of STS is given in 30 min, 6 hours later at the coronary care unit (CCU). When no DLT is observed in any of the patients after 2 gifts of the same dose an extra 3 subjects are enrolled into the next higher dose cohort. If 1 out of 3 patient develops DLT at a specific dose, an extra 3 subjects are enrolled into the same dose cohort. When more than 1 out of 6 patients develop DLT the trial will be terminated because the maximum tolerable dose (MTD) has been exceeded.

Acute Coronary Syndrome

Sodium Thiosulfate Pentahydrate is administered intravenously in 250 centiliters infusion fluid in two doses: first dose with an infusion rate of 16.66 milliliter (ml) per minute (min), second dose with 8.33 ml / min

Sodium Thiosulfate Pentahydrate

University Medical Centre Groningen

Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.

Safety and Tolerability of Sodium Thiosulfate in Patients Presenting With an Acute Coronary Syndrome Undergoing Coronary Angiography Via Trans-radial Approach: a Dose-escalation Study.

DLT defined as all-cause mortality or hemodynamic instability of significant clinical impact:
Hemodynamic instability of significant clinical impact is defined as:
Systolic blood pressure <90 millimeters mercury (mmHg) for >30 min and/or
Catecholamines required to maintain pressure >90 mmHg during systole and
Signs of pulmonary congestion or elevated left-ventricular filling pressures and;
Signs of impaired organ perfusion with ≥1 of the following criteria:
Confusion;
Cool, clammy skin;
Oliguria (urine output <30 ml/h);
Serum-lactate >2.0 mmol/l.
Shock of other causes (hypovolemia, sepsis, bradycardia) are ruled out.

Severe hypersensitivity/allergic reaction such as angio-edema, heavy itch/rash. Outcome measurement will assessed using a binary scale: present (yes) or absent (no)

using a 4-point Likert-scale: 0= none, 1= nauseated but able to eat and/or 1 episode of vomiting in 24 hours, 2= food intake significantly decreased and/or 2-5 episodes of vomiting in 24 hours, 3= intravenous fluids required and/or >5 episodes of vomiting in 24 hours

effect of STS on oxidative stress markers in blood by laboratory analysis of free thiols in blood. Unity: µmol/l. Measurement on different timeframes, starting at T=0, to evaluate the effect of STS on free thiol levels in blood.

myocarditis/mual

Hydroxychloroquine for the Treatment of Patients With Mild to Moderate COVID-19 to Prevent Progression to Severe Infection or Death

A Study of Impact of Anemia on Morbidity and Mortality in Children With Dilated Cardiomyopathy

Analgesic Efficacy of Arnica Montana in Comparison With Diclofenac Sodium Following a Periodontal Surgical Procedure

Safety and Tolerability of Sodium Thiosulfate in Patients With an ACS Undergoing CAG Via Trans-radial Approach.

The Clinical Epidemiology of Hospitalized Dengue Cases in Malaysia

Database tanaman obat terlengkap yang didukung oleh sains